Bloodclotting Disorders: Pfizer & Moderna Pose Similar Risks to AstraZeneca and J&J – VAERS Data

ER Editor: On the topic of blood clotting, we are putting two Children’s Health Defense articles back to back. Both are dated April 16, 2021.

Readers may also be interested in this recent piece by Prof. Michel Chossudovsky noting how Pfizer has been allowed to dominate the vaccine market. See Big Pharma Conglomerate with a Criminal Record: Pfizer “Takes Over” the EU Vaccine Market – 1.8 Billion Doses.

This despite the Pfizer vaccine posing similar health risks.

********

Scientists Warn Pfizer, Moderna Vaccines May Cause Blood Clots, Too

The Johnson & Johnson and AstraZeneca COVID vaccines are under the microscope for their potential to cause blood clots, but scientists warn Pfizer and Moderna vaccines pose similar risks.

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the dayIt’s free.

U.S. and European health officials are scrutinizing the Johnson & Johnson (J&J) and AstraZeneca COVID vaccines for possibly causing blood clots and related blood disorders in vaccine recipients.

But evidence is mounting that the Pfizer and Moderna vaccines cause similar adverse reactions — and U.S. regulatory officials were alerted to that fact as far back as December 2020.

The Centers for Disease Control and Prevention (CDC) on Wednesday convened an emergency meeting of its Advisory Committee on Immunization Practices (ACIP) to determine whether to lift a ban on the J&J vaccine. The ban was put in place Tuesday, after reports of blood clots.

During the meeting, committee members hailed the Pfizer and Moderna mRNA vaccines as great alternatives to the J&J vaccine because there were “no safety signals” — suggesting, unlike the J&J and AstraZeneca adenovirus-based vaccines, mRNA vaccines are not associated with blood clots.

On Tuesday, Peter Marks, director of the Center for Biologics Evaluation and Research at the U.S. Food and Drug Administration (FDA), said on a call with reporters there had been no reported cases of cerebral venous sinus thrombosis (CVST) with thrombocytopenia (low blood platelets that can cause dangerous internal bleeding) following Pfizer and Moderna vaccines.

But Mark’s statement contradicts numerous news reportsrecent studies and even a scientist’s warning directed specifically to Marks late last year — it also contradicts data from the Vaccine Adverse Event Reporting System (VAERS). (ER: See the second article reporting this below.)

Utilizing a search criteria that included reports of blood clots associated with blood coagulation disorders, VAERS yielded a total of 795 reports for all three vaccines from Dec. 14, 2020 through April 1, 2021.

Of the 795 cases reported, there were 400 reports attributed to Pfizer, 337 reports with Moderna and 56 reports with J&J — far more than the eight cases under investigation, including the two additional cases added Wednesday.

Study released today links Pfizer, Moderna to blood clots

study released today by Oxford University found the number of people who developed CVST blood clots after COVID vaccines was about the same for Pfizer, Moderna and AstraZenecaMarketWatch reported. (J&J is not approved for use in the EU, where the study originated).

According to the study, 4 in 1 million people experienced CVST during the two weeks following vaccination with the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine.

Although researchers found a significantly higher incidence of blood clots in people who were infected with COVID, the incidence of blood clots following vaccines was still much higher than the background incidence of 0.41, a strong signal that the vaccines pose this specific risk.

“These findings are consistent with what we know about how vaccine-induced spike proteins can on their own cause cell signaling through interactions with the ACE-2 receptors,” said Lyn Redwood, RN, MSN, president emerita of Children’s Health Defense:

“When this happens, it can result in inflammation and a host of other potentially pathological events in the epithelial lining of the blood vessels which can then trigger pro-inflammatory cytokines capable of activating coagulation systems and down-regulating anticoagulant pathways resulting in clot formation.”

A study published February in the Journal of Hematology examined thrombocytopenia following Pfizer and Moderna vaccination in response to the death of a 56-year-old Florida physician — the first identified patient who died from a brain hemorrhage after receiving Pfizer’s vaccine.

Researchers examined 20 case reports of patients with immune thrombocytopenia (ITP) following vaccination, including 17 without pre‐existing thrombocytopenia using data from the CDC, FDA, U.S. Department of Health and Human Services, Vaccine Adverse Events Reporting System (VAERS), published reports, and communications with patients and treating providers.

After analyzing data, researchers could not exclude the possibility that the Pfizer and Moderna vaccines had the potential to trigger ITP and recommended additional surveillance to determine the incidence of thrombocytopenia post vaccination.

“While the main concern associated with ITP is bleeding, it may come as a surprise that ITP is also associated with a 20% increased risk for blood clots,” Redwood said, pointing to a March 8 article by Dr. Robert Bird, director of haematology at Princess Alexandra Hospital in Brisbane, Australia.

Physicians weigh in on how vaccines might lead to blood clots

The Association of American Physicians and Surgeons (AAPS) said in an April 5 press release all three vaccines approved for emergency use in the U.S. (Pfizer, Moderna and J&J) cause human cells to manufacture the spike protein, which then induces the immune system to make antibodies to that protein.

When a vaccinated person is then exposed to the virus, the immune system will recognize the threat and mount a defense that should at least minimize symptoms.

The spike protein is just a fragment of a virus, so it — or the mRNA that codes for it — cannot cause an infection. However, there are questions about whether the spike protein itself can cause harm as it binds to tissue receptorsAAPS explained.

AAPS physicians and scientists informed the FDA that mRNA products, through spike proteins, may have “the potential to cause microvascular injury [inflammation and small blood clots called microthrombi] to the brain, heart, liver and kidneys in ways that were not assessed in the safety trials.” The FDA has not responded.

At least 37 people have developed a rare platelet disorder after receiving the Pfizer or Moderna shot, including 56-year-old Florida obstetrician Gregory Michael, who developed the disorder three days after receiving the Pfizer product and died 15 days after being vaccinated, AAPS said.

On April 13, Dr. Hooman Noorchashm, a physician-scientist and advocate for ethics who specializes in cardiothoracic surgery, joined Tucker Carlson on his show to discuss blood clots and vaccines.

Noorchashm explained that although it’s a good sign the FDA is taking blood clot complications with J&J seriously, it is missing similar thrombotic complications with Pfizer and Moderna.

“I don’t know why this cluster is sort of affecting J&J. There are certainly other examples of thrombotic events with Pfizer and Moderna that have been entered into the VAERS system,” Noorchashm said.

Scientist warned FDA in December about COVID vaccines and blood clots

On Dec. 8, 2020, before any COVID vaccines received Emergency Use Authorization in the U.S., J. Patrick Whelan, M.D., Ph.D., wrote the FDA about the potential for vaccines designed to create immunity to the SARS-CoV-2 spike protein “to cause microvascular injury and blood clots throughout the body including  the brain, heart, liver and kidneys in ways that were not assessed in the safety trials.”

As The Defender reported in February, Whelan, a Harvard-trained physician with a background in biochemistry, medicine and rheumatology, did not dispute the vaccines’ potential to quickly arrest the spread of the virus — assuming the vaccines prove to actually prevent transmission, which also was not assessed in the clinical trials.

But Whelan cautioned that “it would be vastly worse if hundreds of millions of people were to suffer long-lasting or even permanent damage to their brain or heart microvasculature as a result of failing to appreciate in the short-term an unintended effect of full-length spike protein-based vaccines on other organs.”

The J&J vaccine was paused because six women in the U.S. developed a rare and serious disorder called cerebral venous thrombosis which occurs when a blood clot forms in the brain’s venous sinuses. The clot prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage.

According to Redwood, cerebral venous thrombosis has also been reported in cases of COVID-19 infections. She explained how the same condition that can occur in someone infected with the virus might also occur in someone who gets a COVID vaccine.

“The science has progressed rapidly and we are now aware that the spike protein alone, without COVID infection, is capable of traveling through the body and binding to ACE-2 receptors and activating a host of cell-signaling pathways capable of triggering a wide range of adverse events,” Redwood said.

A landmark study in Nature Neuroscience documented that commercially obtained COVID-19 spike protein (S1) injected into mice not only crossed the blood-brain barrier into the brain, but also the lung, spleen, kidney and liver of the mice.

A second study published in Neurobiology of Disease reported that the SARS-CoV-2 spike protein alone, without the virus, is a potent inductor of endothelial dysfunction through interaction with ACE-2 receptors resulting in a pro-inflammatory response in the vessel linings.

The endothelium is a thin membrane that lines the blood vessels that control vascular relaxation and contraction, as well as enzymes that control blood clotting, immune function and platelet adhesion. Following vascular injury that can be caused by inflammation generated by spike proteins, the endothelium shifts to a pro-thrombotic/pro-coagulant phenotype resulting in blood clot formation and other untoward events.

According to Redwood, it’s “only logical to assume” that when the vaccine creates the identical spike protein that occurs in infection, and which has been identified as the culprit causing a myriad serious and life threatening injuries, “we are going to see these same injuries in individuals who receive the vaccines.”

Redwood said it’s critical that we thoroughly research these vaccine-related injuries before we resume vaccination with spike protein vaccines, especially in children where we have no real data on safety and effectiveness.

********

Latest VAERS Data Show Reports of Blood Clotting Disorders After All Three Emergency Use Authorization Vaccines

VAERS data released today showed 795 reports related to blood clotting disorders with 400 attributed to Pfizer, 337 to Moderna and 56 to Johnson & Johnson between Dec. 14, 2020 and April 8, 2021.

MEGAN REDSHAW

The Defender is experiencing censorship on many social channels. Be sure to stay in touch with the news that matters by subscribing to our top news of the dayIt’s free.

Data released today by the Centers for Disease Control and Prevention (CDC) on the number of injuries and deaths reported to the Vaccine Adverse Event Reporting System (VAERS) following COVID vaccines revealed reports of blood clots and other related blood disorders associated with all three vaccines approved for Emergency Use Authorization in the U.S. — PfizerModerna and Johnson & Johnson (J&J). So far, only the J&J vaccine has been paused because of blood clot concerns.

VAERS is the primary mechanism for reporting adverse vaccine reactions in the U.S. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.

Every Friday, VAERS makes public all vaccine injury reports received through a specified date, usually about a week prior to the release date. Today’s data show that between Dec. 14, 2020 and April 8, a total of 68,347 total adverse events were reported to VAERS, including 2,602 deaths — an increase of 260 over the previous week — and 8,285 serious injuries, up 314 since last week.

Form the 4/8/21 release of VAERS Data

Of the 2,602 deaths reported as of April 8, 27% occurred within 48 hours of vaccination, 19% occurred within 24 hours and 41% occurred in people who became ill within 48 hours of being vaccinated.

In the U.S., 174.9 million COVID vaccine doses had been administered as of April 8. This includes 79.6 million doses of Moderna’s vaccine, 90.3 million doses of Pfizer and 4.9 million doses of the J&J COVID vaccine.

This week’s VAERS data show:

Reports of blood clotting disorders in VAERS

Children’s Health Defense queried the VAERS data for a series of adverse events associated with the formation of clotting disorders and other related conditions. VAERS yielded a total of 795 reports for all three vaccines from Dec. 14, 2020, through April 8.

Of the 795 cases reported, there were 400 reports attributed to Pfizer337 reports with Moderna and 56 reports with J&J — far more than the eight J&J cases under investigation, including the two additional cases added Wednesday.

As The Defender reported today, although the J&J and AstraZeneca COVID vaccines have been under the microscope for their potential to cause blood clots, mounting evidence suggests the Pfizer and Moderna vaccines also cause clots and related blood disorders. U.S. regulatory officials were alerted to the problem as far back as December 2020.

CDC ignores The Defender, no response after 39 days 

According to the CDC’s website, “the CDC follows up on any report of death to request additional information and learn more about what occurred and to determine whether the death was a result of the vaccine or unrelated.”

On March 8, The Defender contacted the CDC with a written list of questions about reported deaths and injuries related to COVID vaccines. We requested information about how the CDC conducts investigations into reported deaths, the status of ongoing investigations reported in the media, if autopsies are being done, the standard for determining whether an injury is causally connected to a vaccine, and education initiatives to encourage and facilitate proper and accurate reporting.

After many attempts to get a response from the CDC, 22 days after our initial outreach a representative from the CDC’s Vaccine Task Force responded, saying the agency had never received our questions — even though the employees we talked to several times said their press officers were working through the questions we sent.

We provided the questions again and set a new deadline of April 7. We’ve reached out multiple times since, but the representative has not answered our emails or returned our calls.

On April 15 we called the CDC’s general media line again and were told they had our list of questions and were unsure why the representative told us she never received them. We were told the COVID response team would be informed and that we should follow up in a few days.

It has been 39 days since we first reached out and have yet to receive answers to our questions.

Johnson & Johnson paused over reports of blood clot

On April 15, The Defender reported that a healthy 43-year old man in Mississippi suffered a stroke hours after being vaccinated with J&J’s COVID vaccine. Brad Malagarie, father of seven, had received the vaccine a little after noon and was found unresponsive by co-workers at his desk.

Also on April 15, the  Cincinnati Enquirer reported that the Ohio Department of Health is monitoring the investigation into what may have caused a 21-year-old University of Cincinnati student to die suddenly last Sunday, about a day after he received the J&J vaccine.

Alicia Shoults, a spokeswoman for the state health department, said the agency is waiting for the completion of a Hamilton County coroner’s report, and “if necessary,” further guidance from the CDC.

The two news stories came just days after federal health officials paused the J&J vaccine.

As The Defender reported April 13, the CDC and U.S. Food and Drug Administration (FDA) called for a temporary but immediate halt to the use of J&J’s COVID vaccine while the agencies investigated the vaccine’s possible link to potentially dangerous blood clots.

In a joint statement, the agencies said the Advisory Committee on Immunization Practices (ACIP) was reviewing clinical data gathered on six women, one who died, between the ages of 18 and 48 years who developed blood clots after receiving the single-dose J&J vaccine.

On April 14, the ACIP held an emergency meeting to vote on whether to lift the pause on J&J’s vaccine or change recommendations for its use. As The Defender reported, the ACIP postponed the vote, extending the pause pending further analysis of data relating to blood clots. The ACIP said it would reconvene for a vote in one week to 10 days.

That same day, J&J revealed two more cases of blood clots — one that occurred in a 25-year-old man who suffered a cerebral hemorrhage during a clinical trial and another case of deep-vein-thrombosis in a 59-year-old woman.

In its review of J&J’s submission for Emergency Use Authorization in February, the FDA initially urged further surveillance of a slight “numerical imbalance” in blood clotting events after receiving the shot. At the time, it was concluded there was “insufficient” data to determine “a causal relationship” with the vaccine and the drugmaker resumed the trial.

As The Defender reported April 12, the rollout of J&J’s COVID vaccine has not been smooth. At the beginning of the month the vaccine maker had to throw out 15 million doses of its vaccine after they were contaminated with AstraZeneca vaccine ingredients at an unapproved manufacturing plant in Baltimore.

The vaccine maker also has been plagued with shutdowns of its vaccine sites prior to the vaccine being paused, multiple reports of COVID breakthrough cases and criticism over its CEO’s $30 million pay package while the company pays out billions for its role in the opioid epidemic.

CDC, multiple states report ‘breakthrough’ COVID cases among fully vaccinated

Cases of fully vaccinated people getting COVID, referred to as “breakthrough” cases, continue to make news.

Calling it a “really good scenario,” the CDC yesterday reported 5,800 cases of COVID in fully vaccinated people. Of the 5,800 cases, 396 required hospitalization and 74 people died, the CDC said.

The CDC said it was “keeping a close eye” on the cases, but that breakthrough cases are to be expected. Tara Smith, a professor of epidemiology at the Kent State University College of Public Health in Ohio, told NBC News:

“This is a really good scenario, even with almost 6,000 breakthrough infections. Most of those have been mildly symptomatic or asymptomatic. That’s exactly what we were hoping for.”

On April 12, the Houston Health Department reported 142 breakthrough cases of COVID that occurred in fully vaccinated people since January, according to ABC 13 News. Vaccine recipients received either two doses of Moderna or Pfizer, or one dose of J&J. The report ruled out those who were said to have contracted the virus 45 days before their second scheduled shot date.

Houston Health Department said there were 2.46 positive cases out of every 10,000 fully-vaccinated people and it was unclear if those who tested positive contracted the original strand of COVID or a newer variant.

Last month, The Defender reported on breakthrough cases in Washington, Florida, South Carolina, Texas, New York, California and Minnesota. On April 6, The Defender reported on 246 breakthrough cases in Michigan, which included three people who died.

Children’s Health Defense asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.

************

Source

••••

The Liberty Beacon Project is now expanding at a near exponential rate, and for this we are grateful and excited! But we must also be practical. For 7 years we have not asked for any donations, and have built this project with our own funds as we grew. We are now experiencing ever increasing growing pains due to the large number of websites and projects we represent. So we have just installed donation buttons on our websites and ask that you consider this when you visit them. Nothing is too small. We thank you for all your support and your considerations … (TLB)

••••

Comment Policy: As a privately owned web site, we reserve the right to remove comments that contain spam, advertising, vulgarity, threats of violence, racism, or personal/abusive attacks on other users. This also applies to trolling, the use of more than one alias, or just intentional mischief. Enforcement of this policy is at the discretion of this websites administrators. Repeat offenders may be blocked or permanently banned without prior warning.

••••

Disclaimer: TLB websites contain copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of “fair use” in an effort to advance a better understanding of political, health, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than “fair use” you must request permission from the copyright owner.

••••

Disclaimer: The information and opinions shared are for informational purposes only including, but not limited to, text, graphics, images and other material are not intended as medical advice or instruction. Nothing mentioned is intended to be a substitute for professional medical advice, diagnosis or treatment.

Be the first to comment

Leave a Reply

Your email address will not be published.


*